A survey of Australian general practitioners' hepatitis C knowledge and management 2 years after subsidised direct-acting antiviral therapy became available.
Gooey M, Wong E, Pedrana A, Allard N, Doyle J, Hellard M, Wade A
Letter in response: Psychiatrists can treat hepatitis C.
Harney BL, Brereton R, Whitton B, Pietrzak D, Paige E, Roberts SK, Birks S, Saraf S, Hellard ME, Doyle JS
A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community-based testing campaign.
Palmer AY, Chan K, Gold J, Layton C, Elsum I, Hellard M, Stoove M, Doyle JS, Pedrana A, Scott N, on the EC Partnership
Early antimicrobial stewardship team intervention on appropriateness of antimicrobial therapy in suspected sepsis: a randomized controlled trial.
Rashidzada Z, Cairns KA, Peel TN, Jenney AW, Doyle JS, Dooley MJ, Cheng AC
Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort.
Carson JM, Hajarizadeh B, Hanson J, O'Beirne J, Iser D, Read P, Balcomb A, Davies J, Doyle JS, Yee J, Martinello M, Marks P, Dore GJ, Matthews GV, REACH-C Study Group
Perceived physical health outcomes of direct-acting antiviral treatment for hepatitis C: a qualitative study.
Goutzamanis S, Horyniak D, Doyle JS, Hellard M, Higgs P, Treatment and Prevention Study group